University of Rhode Island

DigitalCommons@URI
Open Access Master's Theses
2015

A Cross-Sectional Analysis of Bronchodilator Prescribing in COPD
and Cardiovascular Comorbidity
Damilola Tejumola Adesanoye
University of Rhode Island, damilola@my.uri.edu

Follow this and additional works at: https://digitalcommons.uri.edu/theses

Recommended Citation
Adesanoye, Damilola Tejumola, "A Cross-Sectional Analysis of Bronchodilator Prescribing in COPD and
Cardiovascular Comorbidity" (2015). Open Access Master's Theses. Paper 637.
https://digitalcommons.uri.edu/theses/637

This Thesis is brought to you for free and open access by DigitalCommons@URI. It has been accepted for inclusion
in Open Access Master's Theses by an authorized administrator of DigitalCommons@URI. For more information,
please contact digitalcommons@etal.uri.edu.

A CROSS-SECTIONAL ANALYSIS OF
BRONCHODILATOR PRESCRIBING IN COPD AND
CARDIOVASCULAR COMORBIDITY
BY
DAMILOLA ADESANOYE

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE
REQUIREMENTS FOR THE DEGREE OF
MASTER OF SCIENCE
IN
PHARMACEUTCIAL SCIENCES

UNIVERSITY OF RHODE ISLAND
2015

MASTER OF SCIENCE THESIS
OF
DAMILOLA ADESANOYE

APPROVED:
Thesis Committee:
Major Professor

Cynthia Willey
Stephen Kogut
Liliana Gonzalez
Nasser H. Zawia
DEAN OF THE GRADUATE SCHOOL

UNIVERSITY OF RHODE ISLAND
2015

ABSTRACT
Background: Bronchodilators used to treat Chronic Obstructive Pulmonary disease
have been associated with adverse cardiovascular events. Moreover, the high
prevalence of cardiovascular diseases (CVD) in COPD (8-40%) requires an evaluation
of treatment differences between comorbid groups in order to understand the
appropriateness of drug prescribing.
Objective: To determine whether COPD patients with concurrent CVD are less likely
to be prescribed bronchodilators compared to those without CVD.
Methods: A retrospective cross-sectional study was conducted using the 2010
National Ambulatory Medical Care Survey (NAMCS) to quantify the association
between concurrent CVD morbidity and the probability of receiving a bronchodilator
prescription. Visits included patients ≥40 years who had COPD diagnosis. Surveyweighted data were analyzed through descriptive analysis, univariate (unadjusted) and
multivariate (adjusted) logistic regression models. Demographics, patient, physician
and visit characteristics were assessed as covariates in the models.
Results: Out of 11,627,061 ambulatory visits recorded by patients ≥40 years with
COPD diagnosis, majority was male (57%), non-Hispanic White (80%) and used at
least one bronchodilator (55.5%). We found that a significantly lower proportion of
the COPD-CVD group (32.3%) was treated with bronchodilators versus 57.6% for the
non-comorbid group. The effect of CVD on bronchodilator prescribing was modified
by gender, beta-blockers and asthma. CVD patients who were female, not prescribed
beta-blockers and not having concomitant asthma were 94% less likely to be
prescribed bronchodilators compared the non-CVD females with the same

characteristics. On the other hand, males not prescribed beta-blockers and not having
concomitant asthma had 68% lower probability when CVD coexisted with COPD.
Female CVD patients prescribed beta-blockers and not living with asthma had only a
20% chance of being a bronchodilator user than those without CVD. Cardiovascular
disease did not affect the utilization of bronchodilators in males taking beta-blockers
who either had or did not have asthma.
Conclusion: Concurrent CVD diagnosis is a significant factor for reducing the
probability of prescribing bronchodilators for COPD and our findings provide
evidence of variations in bronchodilator prescribing for stratified groups of COPDCVD patients. Most patients with COPD and CVD are less likely to be prescribed
bronchodilators, with the exception of males who were also prescribed beta-blockers.
Thus, this study highlights a specific patient subgroup for whom the guidelines are
less likely to be observed.
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CHAPTER 1

INTRODUCTION

Chronic Obstructive Pulmonary Disease (COPD) is defined as a “preventable and
treatable disease characterized by persistent airflow limitation that is usually
progressive and associated with an abnormal inflammatory response of the lung to
noxious particles or gases. Exacerbations and comorbidities contribute to the overall
severity in individual patients.”1 The disease is clinically diagnosed as one or more of
3 subtypes – chronic bronchitis, emphysema and chronic airway obstruction.2
COPD is the fourth leading cause of chronic morbidity and mortality in the
United States affecting 6.5% of adults (13.7 million diagnosed cases) and leading to
133,575 deaths.2 In 2010, there were 10.3 million physician office visits, 1.5 million
emergency department visits, and 699,000 hospital discharges for COPD.2 Globally,
COPD ranked fifth cause of years lived with disability (YLDs) in the 2010 global
burden of disease study.3 The World Health Organization predicts that COPD will
become the third leading cause of death worldwide by 2030.4 Inevitably, COPD is
and will continue to be a major global health problem.5
Bronchodilators are the mainstay for symptomatic treatment of COPD due to their
ability to relieve bronchial obstruction and airflow limitation, improve emptying of the
lungs and reduce hyperinflation during rest and exercise.6,7 Three major classes are
recommended as first-line agents - beta-(β) 2-agonists, anticholinergics (AC), and
methylxanthines, used alone or in combination or as single or combination drugs.7
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Despite the benefits of bronchodilator agents in the treatment of COPD, patients
may be at an increased risk of cardiovascular (CV) toxicity due to beta-adrenergic
stimulation. Previous studies showing an association between bronchodilators and
adverse cardiovascular events such as arrhythmias, myocardial ischemia, heart failure
and sudden cardiac death, will be discussed in detail in the literature review section.8-13
The potential cardiovascular risk of bronchodilators in COPD has important
therapeutic implications for two main reasons: First of all, the prevalence of
cardiovascular-related diseases (CVD) in COPD is estimated to range from 8% to as
high as 40%1,14-16 making it the most frequent and most important disease group
coexisting with COPD. Secondly, the exclusion of comorbid subjects from clinical
trials often limits the use of trial data in providing practical treatment
recommendations for the real world COPD patient population where multiple
morbidities are highly prevalent.
We hypothesize that cardiac disorders play an independent role in the lesser
probability of receiving a bronchodilator prescription for COPD. The objective of this
study is to provide descriptive data on the classes of bronchodilator medications
prescribed to ambulatory patients with diagnosed COPD in the United States and
examine whether COPD patients with CVD are less likely to be prescribed
bronchodilators compared to COPD patients without CVD.
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CHAPTER 2

REVIEW OF LITERATURE

Etiology and Epidemiology of COPD and its Comorbidities
Cigarette smoking is the dominant and best-studied risk factor for COPD, though
a substantial burden of disease occurs in nonsmokers.17-19 Other etiologic factors such
as advanced age, occupational exposure to dust, fumes and gases, indoor and outdoor
air pollution, airway hyper-responsiveness, asthma, infections and genetic
predisposition (α-antitrypsin deficiency) are also important.1 Furthermore, it has been
increasingly recognized that COPD is more than just a lung disease: it is a complex
heterogeneous systemic disease, frequently associated with other chronic diseases
including coronary heart disease, cardiovascular, respiratory tract, metabolic,
hematological, musculoskeletal, gastrointestinal, renal diseases, psychiatric disorders
and neoplasias.14,15,20-23
The prevalence of comorbidity in COPD has been studied using nationallyrepresentative data, National Health and Nutrition Examination Survey (NHANES)
1999-2008.24 Using a ten-year analytic sample of 14,828 subjects (995 COPD cases)
aged ≥45, subjects with self-reported physician diagnosis of COPD were more likely
than subjects without physician-diagnosed COPD to have coexisting arthritis (54.6%
vs. 36.9%), depression (20.6% vs. 12.5%), osteoporosis (16.9% vs. 8.5%), cancer
(16.5% vs. 9.9%), coronary heart disease (12.7% vs. 6.1%), congestive heart failure
(12.1% vs. 3.9%), and stroke (8.9% vs. 4.6%).24
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Vanfleteren and colleagues used a cluster analysis approach to assess the
prevalence and severity of objectively identified chronic concomitant disorders in a
cohort of 213 patients with moderate to very severe COPD.25

The CIRO CO-

morbidity (CIROCO) study was an observational single-center study and almost all
subjects (97.7%) had one or more comorbidities. More than half (53.5%) of the
patients had at least four comorbidities.
Another study in a sample of COPD patients referred to an Australian outpatient
hospital-based pulmonary rehabilitation program reported that 96% of patients had at
least 1 other chronic conditions and 29% had 5 or more comorbidities.26 Data were
available on 70 patients and 64% of patients had multiple morbidities associated with
cardiovascular disease.
While it is likely that the prevalence of comorbidities in people with COPD is
influenced by common risk factors, such as smoking, advanced age, chronic systemic
inflammation, physical inactivity and low socioeconomic status, studies have
confirmed that concurrent conditions worsen health outcomes independent of preexisting risk factors.26 Comorbidities in COPD lead to lower health-related quality of
life,27,28 more hospitalizations, severe disabilities5 and higher rates of mortality29,30
compared to those without comorbidities.

Burden of comorbid COPD and Cardiovascular disease (CVD)
Observational studies indicate that COPD is associated with a high prevalence of
coronary artery disease, cardiac arrhythmias, cerebrovascular disease, peripheral
vascular disease and congestive heart failure.31-33 In addition, COPD patients with
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CVD pose significantly higher clinical and economic burden on patients and
healthcare system than COPD patients without CVD.
One large retrospective cross-sectional survey involving 618,090 subjects
quantified the association between COPD and diagnosis of CVD and stroke and
revealed that COPD was associated with a fivefold increase in the odds of having had
CVD (OR 4.98, 95% CI 4.85 to 5.81; p<0.001), and a threefold increase in the odds of
having had a stroke (OR 3.34, 95% CI 3.21 to 3.48; p <0.001).34
Curkendall and colleagues found that the prevalence of all cardiovascular
diseases was higher in the COPD group than in the comparison group
subjects(n=11,493) in a retrospective cohort study in Saskatchewan longitudinal health
care databases in Canada.35 After adjusting for cardiovascular risk, odds ratios of
prevalence were: arrhythmia 1.76 (CI: 1.64–1.89), angina 1.61 (CI: 1.47–1.76), acute
myocardial infarction 1.61 (CI: 1.43–1.81), congestive heart failure 3.84 (CI: 3.56–
4.14), stroke 1.11 (CI: 1.02–1.21), pulmonary embolism 5.46 (CI: 4.25–7.02). COPD
patients also had an elevated risk of hospitalization and death (OR 2.7 CI: 1.82–2.36)
due to cardiovascular causes.35 One limitation of the study was the lack of baseline
smoking data which made it difficult to separate the cardiovascular effects of smoking,
a major risk factor for both COPD and CVD, from the effects of COPD.
Similar results on the impact of comorbid COPD-CVD on healthcare utilization
were obtained in a retrospective matched-cohort of 4594 patients each with COPD and
CVD ≥ 40 years of age using administrative claims data and propensity score
technique for matching.36 The data source for this study was the IMS Lifelink
Database containing medical and pharmacy claims data from over 100 different
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managed healthcare plans (encompassing over 60 million patients) in the United
States. The COPD-CVD cohort was about twice as likely than the COPD-only cohort
to require COPD-related hospitalization (OR 1.95; p < 0.001), 47% more likely to
have an ER visit (OR 1.47; p < 0.001) and 62% more likely to require hospitalization
and/or ER visit (OR, 1.62; p <0.001).36 Significant differences in healthcare costs
were found as the average annual all-cause medical costs per patient were $22,755 vs
$8,036 (p<0.001), and total costs were $27,032 vs $11,506 (p<0.001), for COPD-CVD
and for COPD-only groups respectively.36 Corresponding average COPD-related
annual medical costs were $1891 vs $1060 (p<0.001) and total costs were $3295 vs
$2379 (p < 0.001).

COPD Treatment
The most widely applied guideline for treatment is the Global Strategy for the
Diagnosis, Management, and Prevention of COPD (GOLD strategy), revised in 2014
containing summaries of current evidence on management and prevention strategies.1
Four grades of disease are defined according to severity of airflow obstruction; mild
disease A (FEV1 ≥80% predicted), moderate disease B (50% ≤ FEV1 <80%
predicted), C severe disease (30% ≤ FEV1 <50%), and very severe disease D (FEV1
<30% predicted); and the result of this classification leads to treatment choice.
Pharmacotherapy constitutes the major intervention used in COPD patients.
Medications commonly used for COPD are bronchodilators, corticosteroids and
phosphodiesterase-4 inhibitors.37 None of the existing medications have been proven
to change long-term decline in lung function, as such, the main goal of
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pharmacological therapy is to reduce symptoms, decrease the frequency and severity
of exacerbations, improve quality of life and exercise tolerance.1
Non-pharmacological treatment modalities include pulmonary rehabilitation,
oxygen therapy, ventilation support and surgical treatments.1 Regardless of disease
stage, the identification and reduction of risk factors are important in COPD
prevention and treatment. Smoking cessation is the first and most crucial step in
COPD therapy for all COPD patients who smoke, and has greatly influenced the
natural history of COPD and lowered mortality with long-term quit rates as high as
25%.1 Use of smoking cessation products (Bupropion, Varenicline and Nortriptyline)
combined with behavioral support is reported to increase successful smoking cessation
compared with either intervention alone.1,37

Safety of Bronchodilators in COPD
Bronchodilators are the mainstay for symptomatic treatment of COPD due to their
ability to relieve bronchial obstruction and airflow limitation, improve emptying of the
lungs and reduce hyperinflation during rest and exercise.6,7 Bronchodilator treatments
include beta-(β) 2-agonists, anticholinergics (AC), and methylxanthines, used alone or
in combination. They are recommended as first-line agents useful to prevent or reduce
symptoms as-needed or on a regular basis.7 Short-acting bronchodilators are typically
used as rescue medication for immediate symptom relief, routinely in the early disease
stages or in COPD patients with a low symptom burden whereas long-acting
bronchodilators are used as regular maintenance therapy and are generally more
effective and convenient.7 Combinations of bronchodilators may improve efficacy and
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reduce risk of adverse effects rather than increasing the dose of a single agent.7
Inhaled bronchodilators are preferred over oral preparations based on favorable
efficacy and side effect profile.1
Despite the benefits of bronchodilator agents in the treatment of COPD, patients
may be at an increased risk of cardiovascular (CV) toxicity due to beta-adrenergic
stimulation. Evidence on the safety of bronchodilator therapy in COPD is mixed.
There have been reports on the relative safety of bronchodilator use in COPD 38
whereas some researchers have found clinically significant higher risks in the
incidence of cardiovascular events in patients on selected bronchodilator agents than
control groups.8,11,12,39,40
In 2003, Ferguson and coworkers38 evaluated the cardiovascular safety of
salmeterol (a beta-2-agonist), in COPD patients by reviewing safety data from
randomized, double-blind, parallel group, multiple-dose studies. Pooling results from
7 clinical trials, the authors concluded that though both salmeterol and placebo groups
had an increased incidence of adverse CV events with age, concurrent cardiovascular
conditions, and treatment with antiarrhythmic/bradycardic agents, the incidence of
cardiovascular events (8%), including cardiovascular deaths, was similar in both
groups.
However, a meta-analysis of randomized placebo-controlled trials of beta-2
agonists in patients with obstructive airway disease (asthma and COPD) performed a
year later, revealed opposite results.39 This study included longer duration trials in the
analysis to evaluate both the short-term effect on heart rate and potassium
concentrations, and the long-term outcome of adverse cardiovascular events. Adverse
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events included sinus and ventricular tachycardia, syncope, atrial fibrillation,
congestive heart failure, myocardial infarction, cardiac arrest, or sudden death. From
among 33 trials, the conclusion was that beta-2 agonist treatment significantly
increased the risk for a cardiovascular event (relative risk RR 2.54; 95% CI, 1.59 to
4.05) compared to placebo mainly because of the short term effects of tachycardia and
hypokalemia.
In 2008, Macie et al8 examined the relationship between use of inhaled
respiratory drugs in people with chronic obstructive respiratory diseases and
cardiovascular hospitalizations for 5years from 1996 through 2000 using the Manitoba
Health Database. The nested case control study included exposure to beta agonists,
anticholinergic (ipratropium bromide), and inhaled corticosteroids (ICS) and outcomes
were first hospitalizations for supraventricular tachycardia, myocardial infarction,
heart failure or stroke. The likelihood of a hospitalization for SVT, MI, and HF was
significantly increased for those to whom beta agonists [OR 1.68, 95% CI 1.41–2.00],
ipratropium [OR 1.48, 95% CI 1.29–1.70] but not ICS [OR 1.13, 95% CI 0.95–1.35]
were dispensed within 60 days prior to the hospitalization. While it is likely that
bronchodilator use was simply a marker of disease severity and this accounted for
their association with cardiovascular disease, the authors note that ICS was not
associated with these outcomes. The findings on specific drug interactions were that
each case the receipt of cardiac drugs decreased the likelihood of hospitalizations
associated with bronchodilator. For example, bronchodilators increased the risk of
stroke in patients who were not taking cardiac drugs but did not increase the risk of
arrhythmia in the presence of anti-arrhythmic agents.
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In 2012, another nested case-control study involving 6018 subjects with COPD
from the Saskatchewan Cohort Study 9 found that the rate of arrhythmia was elevated
with the new use of ipratropium, a short-acting anticholinergic agent (RR 2.4; 95% CI,
1.4–4.0) and of long-acting β-agonists (RR, 4.5; 95% CI, 1.4–14.4). The researchers
did not find an elevated risk with short-acting beta-2-agonists or methylxanthines and
proceeded to ascertain the results in a larger patient pool. For the reassessment, the
larger Quebec cohort of 76,661 subjects was analyzed.10 They found that the rate of
arrhythmias increased with the new use of short-acting beta-2-agonists (RR, 1.27, 95%
CI, 1.03–1.57) and long-acting beta-2-agonists (RR 1.47; 95% CI, 1.01–2.15), but not
with ipratropium and methylxanthines. This slightly increased risk for short-acting
beta-2 agonists and ipratropium corroborates evidence earlier obtained from the
Manitoba Health Database.8
Tiotropium, a once daily long-acting anticholinergic bronchodilator has also been
reported for safety concerns regarding its use in the COPD patient population. In 2013,
Singh et al 13 reported that an increased risk of all-cause mortality (RR 1.52; 95% CI,
1.06–2.16) and CVD mortality (RR 2.05; 95% CI, 1.06–3.99) was associated with
tiotropium use. Patients with known cardiac disease were also reported to have
significantly high risk of dying from cardiac causes though the risk estimates largely
varied among patients (RR 8.6; 95% CI, 1.1–67.2).
In 2011, a retrospective cohort study of patients attending a Heart Failure (HF)
Disease Management Programme was done by Bermingham and colleagues.11 The
cohort size was 1294 patients (age 70.6+11.5 years) of whom 64% were male and
22.2% were taking β2 agonists. The mean follow-up was 2.9+2.4 years. The study
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intended to address gaps in literature that did not consider the influence of factors such
as the dose, duration, or type of bronchodilator therapy (long acting vs. short acting)
on outcomes. The primary endpoint was the effect of β2 agonist use compared with no
β2 agonist use on mortality using unadjusted and adjusted Kaplan2Meier survival
curves. Beta-agonist users were older, more likely to be male, to have smoked, to have
chronic obstructive pulmonary disease (COPD) and asthma, and less likely to take
beta-blockers. Unadjusted mortality rates for β2 agonist users were found to be
significantly higher than non-β2 agonist users [hazard ratio (HR) 1.304, 95% CI
1.030–1.652, P= 0.028]. Overall mortality rates were similar [HR 1.043, 95% CI
(0.771–1.412), P=0.783] after adjusting for covariates like age, sex, beta-blocker use,
co-morbidity, smoking, COPD, and differences in B-type natriuretic peptide (BNP).
There was no influence of β2 agonist duration of use, dose, or type on outcome in
fully adjusted models.
The possible role of the mode of administration of bronchodilators in observed
differences in treatment effects has also been explored. Available formulations include
metered dose inhalers (MDI), dry powder inhalers (DPI) and soft mist inhalers (SMI).
Using a retrospective study, Verhamme and colleagues12 investigated the risk of
mortality between tiotropium Respimat (an SMI) vs Handihaler (DPI) and showed that
the use of Respimat was associated with about 30% increased mortality (adjusted HR
1.27; 95% CI, 1.03–1.57) compared with Handihaler and the association was strongest
for cardiovascular /cerebrovascular death (adjusted HR 1.56, 95% CI 1.08-2.25). The
reason for this apparent elevated risk is not clear, though it may be related to rapid
peak drug concentrations achieved after mist inhalation.40
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The publications on safety of bronchodilators reveal the likelihood of different
study designs to bias and confounding. Smoking status, non-respiratory drugs with
known arrhythmogenic properties taken concomitantly may bias the study results. The
adverse cardiovascular outcomes may reflect COPD severity or confounding by
indication rather than an adverse effect of bronchodilator therapy. It is also possible
that bronchodilators impose a larger relative risk in people with undiagnosed
cardiovascular disease than in people with known disorders since bronchodilators did
not increase the risk of arrhythmia in the presence of anti-arrhythmic agents.

Utilization of Bronchodilators
Although, long-term decline in lung function is irreversible in COPD,
bronchodilators are recommended to reduce airflow obstruction, reduce the frequency
of exacerbations, improve health status and decrease mortality.1 Therapy usually
includes a short-acting bronchodilator or a long-acting bronchodilator (either a Beta-2agonist or an anticholinergic drug or a methylxanthine) or combination products for
adequate clinical response and tolerance of side effects. 1
A case-control study was conducted on the use of bronchodilators and
arrhythmias in COPD in 2012.9 Out of 469 cases of arrhythmias, the proportion
taking at least one short-acting β-agonist was 37.9%, long-acting β-agonists 1.9%,
Ipratropium bromide 29.4% and Methylxanthine 10.2% compared to the controls
where use was short-acting β-agonist was 35.2%, long-acting β-agonists 1.6%,
Ipratropium bromide 22.2% and Methylxanthine 8.7%. The percentage of β-blocker
users in the study sample was 11.6% and overall cardiovascular medication prescribed

12

is 22.4%. Groenwold and colleagues described the characteristics of a cohort of 3376
COPD/ asthma patients that were beta-agonist users and non-users.41 47.5% were
female, 16.7% of the medication users had diagnosed cardiovascular disease, 29.1%
utilized beta-agonist and 16.7% had prescriptions for anticholinergic drugs.
In addition to the relationship between bronchodilators and cardiovascular disease
in COPD, evidence that medication prescribing may differ by patient demographic
characteristics exists. Treatment differences by sex in the utilization of bronchodilators
and other COPD medications were investigated in a cross-sectional analysis based on
10 year data from two national datasets - National Ambulatory Medical Care Survey
(NAMCS) and the National Hospital Ambulatory Medical Care Survey (NHAMCS).42
Women had a consistently higher proportion of visits with COPD medication
prescriptions than visits by men. The frequency of COPD medications prescribed to
women decreased by 7% (from 73% to 67%) during the study period (1995-2004).
The average number of COPD drug mentions per visit decreased for both women and
men and trends were significantly different between men and women (P < 0.001).
Prescription of methylxanthines decreased in visits by women and men, whereas
prescription of anticholinergics increased continuously in the recent years.
Certainly, the high prevalence of COPD and cardiovascular disease warrant
further study of prescribing patterns in COPD patients with cardiac conditions. Thus,
the purpose of the present study is to determine whether COPD patients in ambulatory
care in the United States have a lower likelihood of being prescribed bronchodilators if
they have concurrent CVD compared to those without CVD.
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CHAPTER 3

METHODOLOGY

Data Source
The 2010 National Ambulatory Medical Care Survey (NAMCS) 43 was the source
of data used to assess COPD patient visits. The NAMCS is designed to collect data on
outpatient visits from non-federally employed office-based physicians in the United
States and it is conducted annually by the National Center for Health Statistics
(NCHS), a division of the Centers for Disease Control and Prevention (CDC). The
survey employs multistage probability sampling design to generate unbiased national
estimates. These data are weighted to be nationally representative of outpatient doctor
visits throughout the United States.
The unit of data collection is the visit or encounter not patient-level. NAMCS
data contains variables on reason for visit, diagnoses, diagnostic/screening services
provided, medication therapy, demographic characteristics of patients, specialty of
physician seen, and certain characteristics of the facility, such as geographic region
and metropolitan status for a randomized sample of patient visits during a randomly
selected 1-week time period. The NAMCS has gained enormous popularity as a choice
dataset to assess national trends in ambulatory medical care utilization and examine
concordance of prescribing patterns with evidence-based treatment guidelines.
Therefore, we consider the dataset suitable for this analysis. The 2010 NAMCS data
were used because they were the most recently available.
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The Institutional Review Board of the University of Rhode Island recognizes that
studies using de-identified, publicly available data do not constitute human subjects
research and granted exempt status for this study.

Analytic sample
The study population consisted of patients aged 40 years and over, who had visits
where chronic obstructive pulmonary disease (COPD) was diagnosed. A patient visit
was included if the COPD International Classification of Diseases, 9th revision,
Clinical Modification ICD-9-CM codes 491, 492 and 496 were listed as 1 of 3
diagnoses for that visit. COPD visits were compared to number of ‘Yes’ responses to
the question “Does the patient now have COPD (Yes/No)” captured on the patient
record form. Figure 1 depicts the inclusion and exclusion criteria.
Further stratification of COPD sub-groups was done by presence or absence of
concurrent diagnosis of cardiovascular conditions of interest. Based on previous
studies, the following cardiovascular diseases were selected: myocardial infarction,
angina, coronary artery disease, cardiac arrhythmias (including tachycardia, atrial
fibrillation, and cardiac arrest), and congestive heart failure. The ICD-9 diagnosis
codes are presented in Table 2.

Variables Specification
The dependent variable is defined as the prescription of a bronchodilator at a
visit (Rx =1 or 0). New or continued bronchodilators recorded in any of the 32
therapeutic class fields were identified using the therapeutic class codes extracted from
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NCHS’s Ambulatory Care Drug Database. Table 3 shows the relevant drug codes. The
drug visits strategy was used instead of drug mentions because we are interested in a
binary response per visit (any bronchodilator treatment Rx=1 vs no bronchodilator
treatment Rx=0) not the total number of times bronchodilators are mentioned in the
entire study population, which was more than one bronchodilator medication for each
ambulatory medical care visit, on the average.
Bronchodilator users were stratified into 4 therapeutic categories (beta-(β) 2agonists, anticholinergics (AC), methylxanthines and combination bronchodilators) to
estimate the proportion of users in each subclass and compare bronchodilator therapy
across CVD exposure variable and other visit characteristics. Table 3 outlines the
commercially available bronchodilator medications according to pharmacological
classes. It should be noted that all bronchodilator-containing drugs whether single
agents or in combination with corticosteroids were included in the outcome variable
definition.
The independent variable of interest is CVD status (Dx =1 or No Dx=0). Age was
modeled as a continuous variable. All other explanatory variables (confounders/effect
modifiers): tobacco smoking, physician specialty, type of healthcare insurance, use of
inhaled corticosteroids, cardiac medications (antiarrhythmic and beta-blockers) and
asthma were measured as categorical variables.
Some study covariates had to be re-coded by removing unknown or missing
responses, collapsing/combining categories and dummy coding. Categorical
independent variables were dummy coded as follows: Race/ethnicity was recoded into
4 groups as Non-Hispanic White (0), Non-Hispanic Black (1), Hispanic (2) and Non-
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Hispanic Other (3). Tobacco use was recoded into Non-current (0) and Current (1).
Use of selected medications including inhaled corticosteroids, antiarrhythmic drugs
and beta-blockers were recoded into No (0) and Yes (1) values. Health insurance
coverage was collapsed into 4 categories and dummy coded - Medicare (0), Private
insurance (1), Medicaid (2) and Other (3). The last group combined other sources of
payment like self-pay, worker’s compensation, no Charge/Charity. Similarly,
physician specialty initially presented as 15 groups was collapsed into 4 groups since
some specialties had no or very few COPD patient visit to have meaningful
interpretation. General/Family Practice, Internal Medicine, Cardiology and Other were
the 4 dummy variables created.

Parametric Assessment
A parametric assessment was done to determine if continuous independent
variables satisfied the assumption of linearity in the logit. Age was the only
continuous variable and was categorized into 3 groups 40-54, 55-74 and 75 & over for
the univariate logistic regression analysis. In the results obtained, the Odds Ratios
followed a positive linear relationship with bronchodilator prescription across the
different age groups (Appendix - Figure 3) and implies it can be coded as either a
continuous or categorical variable. Age was modeled as a continuous variable for the
purpose of this study.

Descriptive Statistics and Modeling Strategy
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Descriptive statistics, univariate and multivariate techniques were used. All
analyses were performed on weighted data as recommended by the NCHS. The patient
visit weighting, as provided, uses the most recently available census data to provide a
stratified representation of the nation’s patient population. All statistical analyses were
done using SAS version 9.3 and the results report weighted information.
For descriptive analysis, the means (with standard error) and proportions of
demographic, clinical and medication utilization characteristics for the study
population were calculated. Rates of drug visits were computed for the sub-categories
of bronchodilator medications. Bivariate associations between the dependent variable
(prescription of one or more bronchodilators) and each independent variable were
separately estimated using univariate logistic regression to obtain unadjusted Odds
Ratios and 95% confidence intervals. This will enable inferences to be deduced about
the true population parameter lies between the confidence limits with 95% certainty.
Confounding and interaction were assessed given that they may bias the
relationship between CVD morbidity and treatment with bronchodilators. Two
multivariate logistic regression (LR) models were developed - one containing
interaction terms plus confounding variables and the other without interaction
(confounders only). First of all, interaction was tested by applying the hierarchy
principle to combinations of variables. This implies that if certain interaction terms are
significant, all lower order components of such terms cannot be deleted and will
remain in any further models considered. Two-way interaction analysis was performed
for the following pairs of variables: CVD and gender, CVD and beta-blockers, CVD
and asthma. Here, the Odds Ratios of prescribing a bronchodilator for COPD in a
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CVD patient is described in terms of the modifying variable, either gender, betablockers or asthma. The multivariate logistic regression (LR) model without
interaction terms was developed.
Both multivariate models included a number of confounders - Age, gender, race,
insurance coverage, asthma, concomitant antiarrhythmic and beta-blocker use, and
physician specialty. Therefore, the multiple regression analysis presented adjusted
models and allowed us to quantify the true association between concurrent COPDCVD morbidity and the probability of receiving a bronchodilator prescription, while
controlling for the effects of other explanatory variables.

Model fit
The next step in the model building procedure was to verify whether or not the
model fitted the data well. Hosmer and Lemeshow goodness-of-fit test and a
likelihood ratio test were conducted on the two multivariate logistic models - full
model with interaction and reduced model without interaction. A final model was
selected based on the adequacy of the fit.
In interpreting the results of the likelihood of prescribing a bronchodilator for
COPD visit of a patient with cardiovascular comorbidity, the Adjusted Odds Ratios
derived from the selected multivariate logistic regression model were used. The 95%
confidence intervals were also calculated for each Odds Ratio.
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CHAPTER 4

FINDINGS

Study Sample Characteristics
An estimated 13,799,072 visits of patients above 40 years had a diagnosis of
COPD occurred in 2010 in the US. This is approximately 1.4% of 1billion annual
office visits. Missing or unknown data were removed leaving 11,627,061 visits in the
analytic sample (Table 4).
The majority of the population (57%) was male, between 55 and 74 years (mean
age, 69 years). Over 80% were Non-Hispanic White and only 8.3% had the cardiac
comorbidities of interest. In terms of the dependent variable, 55.5% of the COPD
visits had a bronchodilator prescription. Source of payment for most visits was
reported to be Medicare (67.5%) which is consistent with the average age ≥ 65 years
eligible for Medicare benefits. 14.4% had a concurrent diagnosis of asthma showing
that some patients may be suffering from the asthma-COPD overlap syndrome. A
small proportion of visits received a prescription for inhaled corticosteroids.
Concomitant use of cardiac medications like anti-arrhythmic agents and beta-blockers
occurred in 14.3% and 23.4%. Cardiologists had a lower percentage of the office visits
compared to Internal Medicine doctors (22.5%), Family physicians (29.4%) and other
specialties (44%).
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Univariate Logistic Regression
The univariate logistic regression analysis performed indicated that most of the
independent variables were significantly associated with the dependent variable (Table
5). Of the 11,672,061 COPD visits, 55.5% had a bronchodilator (BD) prescribed. CVD
visits had lesser odds (OR = 0.35, 95% CI 0.31 - 0.4) than non-CVD visits of receiving
a prescription for a bronchodilator. Females had a lower chance of being prescribed a
bronchodilator compared to males OR= 0.51 95%CI 0.47 - 0.55). In terms of patient
ethnicity, Hispanics and non-Hispanics blacks were about 24% and 78% less likely to
have a bronchodilator medication than Non-Hispanic Whites because they had lower
OR of 0.76 (95%CI 0.62, 0.92) and 0.22 (95%CI 0.2, 0.26) respectively. There was no
significant treatment difference between non-Hispanic whites and non-Hispanics
persons that were neither white nor black (OR = 0.94, 95% CI 0.74 -1.19).
The effect of age on the likelihood of bronchodilator use was significant in the
univariate regression analysis (OR = 1.01, 95% CI 1.01 - 1.02 p= <0.0001). Odds Ratio
of 1.01 implies that the chance of being prescribed the medication increases by 10%
with every 10 years of increasing age. Surprisingly, current smokers were half as likely
to be prescribed one or more bronchodilators compared to those who did not currently
smoke (OR = 0.55 95% CI 0.51 - 0.59). The most likely reason is that those who
eventually developed COPD and were taking medications may have quit smoking and
be in the ‘not current’ category. Again, the implication of the broad categorization of
the tobacco use variable into ‘Current’ and ‘Not current’ smokers is that it excludes
smoking behaviors like ex-smokers, never smokers, heavy or light smokers and we
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cannot compare treatment differences. There was a strong association between asthma
and bronchodilator utilization as revealed by the odds ratio of 4.64, 95% CI 4.07 - 5.3.
The use of inhaled corticosteroids appears to increase the chance that patient is
also taking a bronchodilator (OR=2.84, 95% CI 2.23 - 3.63) while beta-blocker
utilization decreased the probability of concomitant bronchodilator treatment
(OR=0.88, 95% CI 0.80 - 0.95). Antiarrhythmic drugs were not associated with
prevalent BD use (OR = 1.02, 95% CI 0.92 - 1.13).
Physician specialty and type of insurance were associated with increased odds of
receiving a bronchodilator during a doctor visit (p-value < 0.001). A patient who had
private insurance (OR=1.12, 95%CI 1.02 - 1.21) or was seen by a cardiologist (OR=
1.32, 95%CI 1.09 - 1.59) or other specialty (OR=2.13, 95%CI 1.95 - 2.33) was more
likely to get a BD prescription compared to those in the reference category who had
Medicare coverage or were seen by a family doctor or internal medicine specialist
(OR=1.00). Medicaid enrollees did not differ in their treatment with bronchodilators for
COPD diagnosis (OR=1.09, 95%CI 0.91 -1.31).

Multivariate Logistic Regression
Two multivariate logistic regression (LR) models were developed - one containing
interaction terms, exposure and other independent variables and the other without
interaction (exposure plus independent variables only).
In the interaction model, the effects were significant between CVD and each of
three possible modifying variables tested - gender, beta blockers (BB) and asthma since
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all p-values < 0.05. All three modifiers and their product terms with CVD were retained
in the model according to the hierarchy principle.
The reduced model without interaction terms contained the exposure variable
(CVD), and potential confounding variables yielded the results in Table 8. A likelihood
ratio test was conducted based on the null hypothesis of ‘no interaction’ versus
‘interaction’ as alternative hypothesis. The test statistic was 134.4, p-value < 0.0001
produced evidence that the ‘interaction’ model is a significantly better fitting model.
Therefore, the interaction model was selected as the best model and this final choice
guided the interpretation of the parameter estimates and odds ratios. Table 7 displays
the Odds Ratio for the modifying effect of gender, asthma and β-blockers on the
association between CVD and bronchodilator prescribing in COPD.
For effect modification by gender, CVD had a greater effect on bronchodilator
prescribing compared to the non-CVD group in females with neither asthma nor betablocker medication. OR=0.06, 95%CI 0.04-0.09 implies a 94% reduction in the
probability of receiving bronchodilator. In males with no asthma and no beta-blocker
utilization, the effect of CVD was 68% since OR=0.32, 95%CI 0.25-0.40. The highest
difference in the odds of bronchodilator use between CVD and non-CVD groups was
observed in females who had asthma and did not use beta-blockers (OR=0.03, 95%CI
0.02-0.06). Thus, this patient group had the least chance of taking bronchodilators.
CVD was not associated with bronchodilator prescribing in male beta-blocker
users, regardless of asthma status (for male, BB users with asthma OR=0.62 95%CI
0.33-1.16; for male BB users without asthma OR=1.11 95%CI 0.82 - 1.51). Therefore,
cardiovascular disease did not affect the outcome in this category of patients. On the
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contrary, CVD female beta-blocker users without asthma had 79% less probability of
receiving a bronchodilator than similar patients without CVD.
The effect of cardiovascular disease was also modified by concomitant asthma to
different degrees. CVD asthma patients who were males and not taking BB were only
17% as likely to be prescribed bronchodilators compared to those without CVD, that is,
83% less chance of receiving the drug. The effect of CVD was stronger for female
asthma patients taking BBs with 89% lower likelihood, and strongest for female asthma
patients who did not use BB (97% lower likelihood).
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CHAPTER 5

DISCUSSION

Our study revealed that β-agonists were the most frequently prescribed class of
bronchodilators and were prescribed at 56.4% of COPD visits. This fact supports
previous studies.44 We conducted this cross-sectional study to determine whether
prescribing rates of bronchodilators in COPD patients were different in cardiovascular
comorbidities and if so, to what extent patient characteristics modified the prescribing
pattern in ambulatory care in the United States.
We found that most COPD patients, who had been diagnosed with cardiovascular
disease, were prescribed bronchodilators less frequently than were those who had
COPD without cardiovascular diagnosis, but that this relationship was modified by
patient characteristics. This pattern was more evident for females, whereas males had
less pronounced differences between CVD and non-CVD groups. Our finding was
consistent with literature on treatment differences in bronchodilator utilization for
comorbid groups. 45
There were significant interactions between cardiovascular disease and gender, βblocker and asthma, shown in Table 7. The presence of cardiovascular diagnosis
significantly decreased the likelihood of bronchodilator prescription by 97% for
females who were not taking beta-blockers but had asthma (OR=0.03, 95% CI 0.020.06). Males with similar characteristics had 83% reduced odds of taking
bronchodilators. This was not entirely suspected as a previous cross-sectional study by
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Suh et al based on 10 years data from the NAMCS and hospital files (NHAMCS) 42
found that women had a consistently higher proportion of visits with COPD medication
prescriptions than visits by men.
No significant difference in bronchodilator utilization between CVD and non-CVD
groups was observed with the use of beta-blockers in males who were either asthma
(OR=0.62 95% CI 0.33-1.16) or non-asthma patients (OR=1.11 95%CI 0.82-1.51). A
possible explanation may be that the concurrent use of beta-blockers for cardiac
conditions and bronchodilators (which are majorly beta-agonists) in patients with
multiple morbidities, leads to opposing pharmacological activity due to interaction
between these medications. Other studies have found that the effects of β-agonists may
be diminished by β-blockers and vice-versa.46 In the Cooperative Cardiovascular
Project47, β-blocker use was not associated with lower mortality among patients
receiving concurrent beta-agonists. Subjects enrolled in the Veterans Administration’s
ACQUIP trial who received both beta-blockers and beta-agonists had no increase in
risk of acute coronary syndromes.48 However, we did not observe this nullifying effect
among females with comparable characteristics. The effect of CVD on bronchodilator
prescribing in females taking beta-blockers with coexisting asthma was about 79% less
than those without CVD (OR=0.21 95%CI 0.14 - 0.30). These results point to the fact
that the effect of CVD on prescribing differs between males and females who
concurrently use beta-blockers and bronchodilators (mainly beta-agonists) and suggest
more conservative prescribing practices for females than for males.
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Strengths and Limitations
One of the strengths of the current study is the dataset. The NAMCS provides a
national perspective on drug utilization in ambulatory medical care. We included
patients with COPD diagnosis, race and ethnicity data, sources of payment, all regions
and physician categories across the United States. Standard ICD-(-CM coding used for
all the diagnoses aided identification of the COPD and cardiovascular conditions of
interest. Apart from the ICD-9 codes, the survey included separate physician-defined
variables for chronic conditions like COPD, Congestive heart failure, Ischemic heart
disease. For example, the questions on the patient record form came in form of “Does
the patient now have COPD (Yes/No)”. We could compare responses from both
approaches to increase the reliability of patients’ diagnosis. The Ambulatory Drug
database had specific drug codes for each therapeutic class which were employed for
easy analysis of medication utilization for bronchodilators, cardiovascular drugs and
their therapeutic subcategories. The inclusion of these details helped to evaluate
differences in the use of bronchodilators across patient characteristics.
This study has limitations related to the study design and datasource. Because of
the cross-sectional nature of the study design, the disease diagnosis and use of
medications prescribed were collected at a single point in time, precluding the
researcher from establishing the temporal relationship between onset of cardiovascular
disease and initiation of bronchodilator treatment.
Bronchodilator prescriptions were assumed to be directly indicated for COPD
treatment which may not be accurate. The NAMCS data has a comprehensive list of
medications and diagnosis codes documented for each patient encounter but since there
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is no clear match between the prescribed medications and ICD-9 diagnosis codes, we
could not verify the specific diagnosis for which bronchodilators are being prescribed.
Future improvements to the survey design to establish a link between these disease
condition and medications prescribed would be helpful to researchers. The dataset did
not contain specific information that would indicate that patients may have a
contraindication or past drug-related adverse event, thereby preventing the use of one
or more bronchodilator medication.
Another limitation is the type of drug formulation. 17.4% of the prescribed
products per visit were fixed combinations of different classes of bronchodilators or a
bronchodilator in addition to an inhaled corticosteroid. However, we categorized and
assessed them like any other bronchodilator in the study because evidence suggests
inhaled corticosteroid present less cardiovascular risk unlike oral corticosteroids that
may cause sodium and fluid retention leading to elevated blood pressure and adverse
cardiovascular effects.49,50 Combination regimens are substantially utilized in COPD
due to the increased effectiveness, reduced burden of medication use and increased
adherence that can potentially achieved with this agents. Therefore, all bronchodilatorcontaining drugs whether single agents or in combination with corticosteroids were
included in the definition of the outcome variable.
We considered including disease severity measures as covariates in this study but
were unable to because the cross-sectional data did not contain clinical outcomes or
follow-up information. Prescribing practices often differ from provider to provider and
it may be worth investigating predictors of bronchodilator prescribing among
physicians. Future research should attempt documenting the physician characteristics
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influencing bronchodilator prescribing for COPD patients. The outcome of this type of
analysis can provide inputs for shaping integrated disease management programs for
concurrent COPD and CVD conditions.
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CHAPTER 6

CONCLUSION

Despite considerable research interest in the potential risk of cardiac events
associated with use of bronchodilators in COPD patients, few studies have analyzed
the real-world prescribing rates of this highly utilized COPD therapy in
cardiovascular disease. This study presents a unique national perspective to
understand the effect of CVD on prescribing practices of bronchodilators in the
United States.
Concurrent CVD diagnosis is a significant factor for reducing the probability of
prescribing bronchodilators for COPD and the odds of prescribing were further
decreased due to differences in gender, asthma and beta-blocker use. CVD patients
who were female, not taking beta-blockers and not having concomitant asthma were
94% less likely to be taking bronchodilators compared the non-CVD females with
same characteristics. On the other hand, males not taking beta-blockers and not
having concomitant asthma had 68% lower probability when CVD coexisted with
COPD. Female CVD patients taking beta-blockers and not living with asthma had
only 20% chance of being a bronchodilator user than those without CVD. It is
noteworthy that the general pattern observed in these national data is consistent with
treatment guidelines that advise using bronchodilators with caution in the comorbid
COPD-CVD patient population, however cardiovascular disease did not affect the
utilization of bronchodilators in males taking beta-blockers.

30

Our findings provide evidence that most patients with COPD and CVD are less likely
to be prescribed bronchodilators, with the exception of males who were also
prescribed beta-blockers. Thus this study highlights a specific patient subgroup for
whom the guidelines are less likely to be observed.
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Appendix A: University of Rhode Island IRB Exemption Letter
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Table 1: Selected Information on the 2010 NAMCS Data and Analytic Sample

Survey Item

Data

Unweighted number of office visits recorded by participating
physicians
Weighted number of representative ambulatory-based medical
care office visits in the United States
Unweighted number of office visit records for COPD patients
40 years and over, without missing/unknown values
Weighted number of representative COPD office visits for
patients 40+years in the United States
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2010
NAMCS

Analytic
sample

Result
31, 229
1,008,802,005
263
11,627,061

Table 2: ICD-9-CM diagnosis codes for COPD and cardiovascular diseases

Diagnosis
code

Study
variable

Chronic bronchitis

491.xx

COPD

Emphysema

492.xx

COPD

Chronic airway obstruction

496.xx

COPD

Acute myocardial infarction

410.xx

CVD

Angina pectoris

413.xx

CVD

Coronary artery disease
Cardiac arrhythmias (including tachycardia, atrial
fibrillation)

414.xx

CVD

427.xx

CVD

428.xx

CVD

Description of Diagnosis

Congestive heart failure
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Table 3: List of NAMCS 2010 Pharmacologic classes and codes of bronchodilator
medications
Drug
therapeutic
category
Level 2

Drug
therapeutic
category
Level 3

Beta-2-agonists
(code 180)

Bronchodilators
(code 125)

Anticholinergics
(code 299)

Sub-class

Short-acting
Beta-2-agonists
(SABA)
Long-acting
Beta-2-agonists
(LABA)
Short-acting
Anticholinergics
Long-acting
Anticholinergics

Methylxanthines
(code 126)

Methylxanthines

Combination
bronchodilators
(code 181)

Beta-2-agonists
plus
anticholinergic
Beta-2-agonists
plus
corticosteroid
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Generic
names
Albuterol,
levalbuterol,
metaprotenerol
Arformoterol,
formoterol,
salmeterol,
Ipratropium
Aclidinium,
tiotropium
Aminophylline
, dyphylline,
theophylline
Albuterol/iprat
ropium,

Brand
names
available in
2010
Ventolin,
Proair,
Proventil,
VoSpire,
Xopenex,
Brovana,
Foradil,
Perforomist,
Serevent,
Atrovent
Tudorza
Pressair,
Spiriva
Lufyllin,
Jay-Phyl,
Theo-24,
Elixophyllin,
Uniphyl,
Combivent,

Salmeterol/Flut Advair
icasone

Table 4: Demographic and Clinical characteristics of COPD visits (N=11,627,061)
Weighted Estimates ┼

Characteristic
Age

Gender
Race/ethnicity

Region

Tobacco Use
Cardiovascular disease CVD**
Bronchodilator prescription
Type of Bronchodilator
prescribed

Concomitant Asthma
Inhaled corticosteroid use
Antiarrhythmic drugs
Beta-blockers
Payment Source

Physician specialty

Mean age *
40 – 54
55 – 74
≥ 75
Female
Male
Non-Hispanic White
Non-Hispanic Black
Hispanic
Non-Hispanic Other
Northeast
Midwest
South
West
Current
Not current
Yes
No
Yes
No
Beta-2- agonist
Anticholinergics
Methylxanthines
Combination bronchodilators
Yes
No
Yes
No
Yes
No
Yes
No
Private Insurance
Medicare
Medicaid
Other
General/Family Practice
Internal Medicine
Cardiology
Other specialty

No. (‘000s)
69.2 (0.9)
1331
6296
4000
4999
6628
9545
1376
418
289
1556
1928
6097
2046
7392
4235
960
10667
6456
5171
3638
1604
89
1126
1677
9950
379
11248
1658
9969
2726
8901
2996
7848
505
277
3424
2620
489
5094

%
11.4
54.1
34.4
43.0
57.0
82.1
11.8
3.6
2.5
13.4
16.6
52.4
17.6
63.6
36.4
8.3
91.7
55.5
44.5
56.4
24.8
1.4
17.4
14.4
85.6
3.3
96.7
14.3
85.7
23.4
76.6
25.8
67.5
4.3
2.4
29.4
22.5
4.2
44

* Mean age and standard error in years
** CVD includes myocardial infarction (0.05%), angina (0.3%), coronary artery disease (5.15%), cardiac
arrhythmias 2.0% (including tachycardia, atrial fibrillation), congestive heart failure (0.7%)
┼ Weighted values represent the sample adjusted to represent national visit characteristics
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Table 5: Utilization of bronchodilator by CVD status

Type of
bronchodilator (Yes)

%
CVD

%
No CVD

Beta-2- agonist

5.1

94.9

Anticholinergics

6.9

93.1

p-value

< 0.0001
Methylxanthines

0

100

Combination
bronchodilators

1.1

98.9
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Table 6: Univariate Logistic Regression Analysis of NAMCS 2010 COPD visits of
patients ≥ 40years with bronchodilator prescription by covariates
% of COPD
visits receiving
Bronchodilator
prescription

Unadjusted
Odds Ratio
(95% CI)

Yes

32.3

0.35 (0.31, 0.4)

No

57.6

1.00 (reference)

Female

46.1

0.51 (0.47,0.55)

Male

62.7

1.00 (reference)

55.5

1.01 (1.01,1.02)

Non-Hispanic White

59.9

1.00 (reference)

Non-Hispanic Black

25.1

0.22 (0.2,0.26)

Hispanic

53.1

0.76 (0.62,0.92)

Non-Hispanic Other

58.4

0.94 (0.74,1.19)

Current

46.1

0.55 (0.51,0.59)

Not current

60.9

1.00 (reference)

Yes

82.8

4.64 (4.07,5.3)

No

50.9

1.00 (reference)

Yes

77.5

2.84 (2.23,3.63)

No

54.8

1.00 (reference)

Yes

55.9

1.02 (0.92,1.13)

No

55.5

1.00 (reference)

Yes

53.0

0.88 (0.8,0.95)

No

56.3

1.00 (reference)

Private Insurance

57.6

1.12 (1.02,1.21)

Medicare

55.0

1.00 (reference)

Medicaid

57.1

1.09 (0.91,1.31)

Other
General/Family
Practice
Internal Medicine
Cardiology
Other specialty

45.6

0.69 (0.54,0.88)

48.8

1.00 (reference)

42.1
55.6
67.0

0.76 (0.69,0.85)
1.32 (1.09,1.59)
2.13 (1.95,2.33)

Characteristic

Cardiovascular disease

Gender

Age
Race/ethnicity

Tobacco Use

Patients with Asthma

Inhaled corticosteroid use

Antiarrhythmic drugs

Beta blockers

Health Insurance type

Physician specialty
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<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

<0.0001

0.7159

0.0023

0.0005

<0.0001

Table 7: Modification of the effect of cardiovascular disease comorbidity on
bronchodilator prescription in COPD

Exposure
(CVD)

Effect modifier (s) *

Adjusted
Odds
Ratio

95%
confidence
limits

Effect measure
modification **

Yes
No

Male, no Asthma, no β-blocker
Male, no Asthma, no β-blocker

0.32
1.00

0.25 - 0.40
reference

68%

Yes

Male, Asthma, no β-blocker

0.17

0.10 - 0.31

83%

No

Male, Asthma, no β-blocker

1.00

reference

Yes

Male, no Asthma, β-blocker

1.11

0.82 - 1.51

No

Male, no Asthma, β-blocker

1.00

reference

Yes

Male, Asthma, β-blocker

0.62

0.33 - 1.16

No

Male, Asthma, β-blocker

1.00

reference

Yes
No

Female, no Asthma, no β-blocker
Female, no Asthma, no β-blocker

0.06
1.00

0.04 -0.09
reference

94%

Yes

Female, Asthma, no β-blocker

0.03

0.02 - 0.06

97%

No

Female, Asthma, no β-blocker

1.00

reference

Yes

Female, no Asthma, β-blocker

0.21

0.14 - 0.30

No

Female, no Asthma, β-blocker

1.00

reference

Yes

Female, Asthma, β-blocker

0.11

0.07 - 0.19

No

Female, Asthma, β-blocker

1.00

reference

None

None

79%

89%

* Effect modifiers are gender, asthma and β-blockers
** Effect measure modification was calculated by the difference between the odds in the CVD
group and the non-CVD comparison group, on a percent-scale
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Table 8: Multivariate Logistic Regression Analysis of bronchodilator
prescription in COPD without effect modification

Characteristic
Main effects
CVD
Gender
Beta blockers
Asthma
Race/ethnicity

Tobacco Use
Inhaled corticosteroid use
Antiarrhythmic drugs
Health Insurance type

Physician specialty

Adjusted Odds Ratio
(95% CI)

Factor
Yes
No
Female
Male
Yes
No
Yes
No
Non-Hispanic White
Non-Hispanic Black
Hispanic
Non-Hispanic Other
Current
Not current
Yes
No
Yes
No
Private Insurance
Medicare
Medicaid
Other
General/Family Practice
Internal Medicine
Cardiology
Other specialty
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0.30 (0.25 - 0.35)
1.00 (reference)
0.50 (0.46 - 0.55)
1.00 (reference)
0.90 (0.82 - 1.00)
1.00 (reference)
4.85 (4.17 - 5.63)
1.00 (reference)
1.00 (reference)
0.24 (0.21 - 0.28)
0.39 (0.32 - 0.49)
1.49 (1.15 - 1.93)
0.55 (0.50 - 0.61)
1.00 (reference)
1.52 (1.15 - 2.00)
1.00 (reference)
1.71 (1.50 - 1.94)
1.00 (reference)
1.47 (1.32 - 1.62)
1.00 (reference)
1.68 (1.34 - 2.10)
1.15 (0.85 - 1.55)
1.00 (reference)
0.72 (0.64 - 0.81)
1.94 (1.56 - 2.43)
2.00 (1.81 - 2.22)

Figure 1: Flow Chart of application of study eligibility criteria
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Figure 2: Two-way contingency table for Primary IV and DV
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Figure 3: Parametric Assessment of Continuous Variables

Reference class= agecat2

Age
category

Mid-point

% Frequency

Odds Ratio

agecat 1

40 - 54

47.5

11.4

0.709

agecat 2

55 - 74

65

54.1

1.00

agecat 3

75 & over

89.5

34.4

1.378

Effect

43

LIST OF REFERENCES
1.

Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global
Strategy for the Diagnosis, Management and Prevention of COPD. 2014;
Available from: http://www.goldcopd.org/. Accessed November 20, 2014.

2.

Ford ES, Croft JB, Mannino DM, Wheaton AG, Zhang X, Giles WH. COPD
surveillance—United States, 1999-2011. Chest. 2013;144(1):284-305.

3.

Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for
1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis
for the Global Burden of Disease Study 2010. The Lancet.
2012;380(9859):2163-2196.

4.

World Health Organization. Global surveillance, Prevention and Control of
Chronic Respiratory Diseases: A Comprehensive Approach. 2007; Available
from: http://whqlibdoc.who.int/publications/2007/9789241563468_eng.pdf.
Accessed January 2, 2015.

5.

Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease:
current burden and future projections. European Respiratory Journal.
2006;27(2):397-412.

6.

Cazzola M, Matera MG. Bronchodilators: Current and Future. Clinics in Chest
Medicine. 2014;35(1):191-201.

7.

Hanania NA, Donohue JF. Pharmacologic Interventions in Chronic
Obstructive Pulmonary Disease. Proceedings of the American Thoracic
Society. 2007;4(7):526-534.

8.

Macie C, Wooldrage K, Manfreda J, Anthonisen N. Cardiovascular morbidity
and the use of inhaled bronchodilators. International Journal of Chronic
Obstructive Pulmonary Disease. 2008;3(1):163.

9.

Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and
the risk of arrhythmia in copd: Part 1: saskatchewan cohort study. Chest.
2012;142(2):298-304.

44

10.

Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and
the risk of arrhythmia in copd: Part 2: reassessment in the larger quebec cohort.
Chest. 2012;142(2):305-311.

11.

Bermingham M, O'Callaghan E, Dawkins I, et al. Are beta2-agonists
responsible for increased mortality in heart failure? European Journal of Heart
Failure. 2011;13(8):885-891.

12.

Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG,
Sturkenboom MC. Use of tiotropium Respimat Soft Mist Inhaler versus
HandiHaler and mortality in patients with COPD. European Respiratory
Journal. 2013;42(3):606-615.

13.

Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic
effects of inhaled anticholinergic medications. Thorax. 2013;68(1):114-116.

14.

Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of
diabetes, hypertension and cardiovascular disease in COPD. European
Respiratory Journal. 2008;32(4):962-969.

15.

Baty F, Putora PM, Isenring B, Blum T, Brutsche M. Comorbidities and
burden of COPD: a population based case-control study. PloS One.
2013;8(5):e63285.

16.

Chatila WM, Thomashow BM, Minai OA, Criner GJ, Make BJ. Comorbidities
in Chronic Obstructive Pulmonary Disease. Proceedings of the American
Thoracic Society. 2008;5(4):549-555.

17.

Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers.
Lancet. 2009;374(9691):733-743.

18.

Bang KM. Chronic obstructive pulmonary disease in nonsmokers by
occupation and exposure: a brief review. Current Opinion in Pulmonary
Medicine. 2015;21(2):149-154.

19.

Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers:
results from the population-based burden of obstructive lung disease study.
Chest. 2011;139(4):752-763.

45

20.

Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD.
European Respiratory Journal. 2009;33(5):1165-1185.

21.

Cavailles A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD.
European Respiratory Review: An Official Journal of the European
Respiratory Society. 2013;22(130):454-475.

22.

Smith MC, Wrobel JP. Epidemiology and clinical impact of major
comorbidities in patients with COPD. International Journal of Chronic
Obstructive Pulmonary Disease. 2014;9:871-888.

23.

Pumar MI, Gray CR, Walsh JR, Yang IA, Rolls TA, Ward DL. Anxiety and
depression-Important psychological comorbidities of COPD. Journal of
Thoracic Disease. 2014;6(11):1615-1631.

24.

Schnell K, Weiss CO, Lee T, et al. The prevalence of clinically-relevant
comorbid conditions in patients with physician-diagnosed COPD: a crosssectional study using data from NHANES 1999-2008. BMC Pulmonary
Medicine. 2012;12(26):1471-2466.

25.

Vanfleteren L, Spruit MA, Groenen M, et al. Clusters of Comorbidities Based
on Validated Objective Measurements and Systemic Inflammation in Patients
with Chronic Obstructive Pulmonary Disease. American Journal of
Respiratory and Critical Care Medicine. 2013;187(7):728-735.

26.

Noteboom B, Jenkins S, Maiorana A, Cecins N, Ng C, Hill K. Comorbidities
and medication burden in patients with chronic obstructive pulmonary disease
attending pulmonary rehabilitation. Journal of Cardiopulmonary
Rehabilitation and Prevention. 2014;34(1):75-79.

27.

Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and
chronic obstructive pulmonary disease: effect on mortality, hospital
readmission, symptom burden, functional status, and quality of life. Archives
of Internal Medicine. 2007;167(1):60-67.

28.

Burgel PR, Escamilla R, Perez T, et al. Impact of comorbidities on COPDspecific health-related quality of life. Respiratory Medicine. 2013;107(2):233241.

46

29.

Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of
comorbidities. European Respiratory Journal. 2006;28(6):1245-1257.

30.

Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in
patients with chronic obstructive pulmonary disease. American Journal of
Respiratory and Critical Care Medicine. 2012;186(2):155-161.

31.

Falk JA, Kadiev S, Criner GJ, Scharf SM, Minai OA, Diaz P. Cardiac Disease
in Chronic Obstructive Pulmonary Disease. Proceedings of the American
Thoracic Society. 2008;5(4):543-548.

32.

Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and
cardiovascular disease. Translational Research. 2013;162(4):237-251.

33.

Güder G, Brenner S, Störk S, Hoes A, Rutten FH. Chronic obstructive
pulmonary disease in heart failure: accurate diagnosis and treatment. European
Journal of Heart Failure. 2014;16(12):1273-1282.

34.

Feary JR, Rodrigues LC, Smith CJ, Hubbard RB, Gibson JE. Prevalence of
major comorbidities in subjects with COPD and incidence of myocardial
infarction and stroke: a comprehensive analysis using data from primary care.
Thorax. 2010;65(11):956-962.

35.

Curkendall SM, deLuise C, Jones JK, et al. Cardiovascular Disease in Patients
with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada:
Cardiovascular Disease in COPD Patients. Annals of Epidemiology.
2006;16(1):63-70.

36.

Dalal AA, Shah M, Lunacsek O, Hanania NA. Clinical and economic burden
of patients diagnosed with COPD with comorbid cardiovascular disease.
Respiratory Medicine. 2011;105(10):1516-1522.

37.

Osthoff M, Jenkins C, Leuppi J. Chronic obstructive pulmonary disease--a
treatable disease. Swiss Medical Weekly. 2013;143:w13777.

38.

Ferguson GT, Funck-Brentano C, Fischer T, Darken P, Reisner C.
Cardiovascular safety of salmeterol in COPD. Chest. 2003;123(6):1817-1824.

47

39.

Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of betaagonists in patients with asthma and COPD: a meta-analysis. Chest.
2004;125(6):2309-2321.

40.

Van Noord JA, Cornelissen PJ, Aumann JL, Platz J, Mueller A, Fogarty C.
The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or
HandiHaler in COPD patients. Respiratory Medicine. 2009;103(1):22-29.

41.

Groenwold RH, de Vries F, de Boer A, et al. Balance measures for propensity
score methods: a clinical example on beta-agonist use and the risk of
myocardial infarction. Pharmacoepidemiology and Drug Safety.
2011;20(11):1130-1137.

42.

Suh DC, Lau H, Pokras SM, Choi IS, Valiyeva E. Sex differences in
ambulatory visits for chronic obstructive pulmonary disease, based on the
National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey from 1995 to 2004. Respiratory Care.
2008;53(11):1461-1469.

43.

National Center for Health Statistics. National Ambulatory Medical Care
Survey. 2010; Available at
http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm. Accessed February
12, 2015.

44.

Ford ES, Mannino DM, Wheaton AG, et al. Trends in the use,
sociodemographic correlates, and undertreatment of prescription medications
for chronic obstructive pulmonary disease among adults with chronic
obstructive pulmonary disease in the United States from 1999 to 2010. PloS
One. 2014;9(4):e95305.

45.

Drivenes E, Ostrem A, Melbye H. Predictors of ICS/LABA prescribing in
COPD patients: a study from general practice. BMC Family Practice.
2014;15:42.

46.

Hawkins NM, Petrie MC, MacDonald MR, et al. Heart Failure and Chronic
Obstructive Pulmonary Disease: The Quandary of Beta-Blockers and BetaAgonists. Journal of the American College of Cardiology. 2011;57(21):21272138.

47.

Chen J, Radford MJ, Wang Y, Marciniak TA, Krumholz HM. Effectiveness of
beta-blocker therapy after acute myocardial infarction in elderly patients with
48

chronic obstructive pulmonary disease or asthma. Journal of the American
College of Cardiology. 2001;37(7):1950-1956.
48.

Au DH, Curtis JR, Every NR, McDonell MB, Fihn SD. Association between
inhaled beta-agonists and the risk of unstable angina and myocardial infarction.
Chest. 2002;121(3):846-851.

49.

Amabile CM, Spencer AP. Keeping your patient with heart failure safe: A
review of potentially dangerous medications. Archives of Internal Medicine.
2004;164(7):709-720.

50.

Souverein PC, Berard A, Van Staa TP, et al. Use of oral glucocorticoids and
risk of cardiovascular and cerebrovascular disease in a population based case–
control study. Heart. 2004;90(8):859-865.

49

BIBLIOGRAPHY
Amabile, C. M. and A. P. Spencer. "Keeping Your Patient with Heart Failure Safe: A
Review of Potentially Dangerous Medications." Archives of Internal Medicine
164, no. 7 (2004): 709-720.

Au, D. H., J. R. Curtis, N. R. Every, M. B. McDonell and S. D. Fihn. "Association
between Inhaled Beta-Agonists and the Risk of Unstable Angina and
Myocardial Infarction." Chest 121, no. 3 (2002): 846-51.

Bang, K. M. "Chronic Obstructive Pulmonary Disease in Nonsmokers by Occupation
and Exposure: A Brief Review." Current Opinion in Pulmonary Medicine 21,
no. 2 (2015): 149-54.

Barnes, P. J. and B. R. Celli. "Systemic Manifestations and Comorbidities of Copd."
European Respiratory Journal 33, no. 5 (2009): 1165-85.

Baty, F., P. M. Putora, B. Isenring, T. Blum and M. Brutsche. "Comorbidities and
Burden of Copd: A Population Based Case-Control Study." PloS One 8, no. 5
(2013): e63285.

Bermingham, M., E. O'Callaghan, I. Dawkins, S. Miwa, S. Samsudin, K. McDonald
and M. Ledwidge. "Are Beta2-Agonists Responsible for Increased Mortality in
Heart Failure?" European Journal of Heart Failure 13, no. 8 (2011): 885-91.

Bhatt, Surya P. and Mark T. Dransfield. "Chronic Obstructive Pulmonary Disease and
Cardiovascular Disease." Translational Research 162, no. 4 (2013): 237-251.

Burgel, P. R., R. Escamilla, T. Perez, P. Carre, D. Caillaud, P. Chanez, C. Pinet, G.
Jebrak, G. Brinchault, I. Court-Fortune, J. L. Paillasseur, N. Roche and
Initiatives Bpco Scientific Committee. "Impact of Comorbidities on Copd50

Specific Health-Related Quality of Life." Respiratory Medicine 107, no. 2
(2013): 233-41.

Cavailles, A., G. Brinchault-Rabin, A. Dixmier, F. Goupil, C. Gut-Gobert, S.
Marchand-Adam, J. C. Meurice, H. Morel, C. Person-Tacnet, C. Leroyer and
P. Diot. "Comorbidities of Copd." European Respiratory Review: An Official
Journal of the European Respiratory Society 22, no. 130 (2013): 454-75.

Cazzola, Mario and Maria Gabriella Matera. "Bronchodilators: Current and Future."
Clinics in Chest Medicine 35, no. 1 (2014): 191-201.

Chatila, Wissam M., Byron M. Thomashow, Omar A. Minai, Gerard J. Criner and
Barry J. Make. "Comorbidities in Chronic Obstructive Pulmonary Disease."
Proceedings of the American Thoracic Society 5, no. 4 (2008): 549-555.

Chen, J., M. J. Radford, Y. Wang, T. A. Marciniak and H. M. Krumholz.
"Effectiveness of Beta-Blocker Therapy after Acute Myocardial Infarction in
Elderly Patients with Chronic Obstructive Pulmonary Disease or Asthma."
Journal of the American College of Cardiology 37, no. 7 (2001): 1950-6.

Curkendall, Suellen M., Cynthia deLuise, Judith K. Jones, Stephan Lanes, Mary Rose
Stang, Earl Goehring Jr and Dewei She. "Cardiovascular Disease in Patients
with Chronic Obstructive Pulmonary Disease, Saskatchewan Canada:
Cardiovascular Disease in Copd Patients." Annals of Epidemiology 16, no. 1
(2006): 63-70.

Dalal, Anand A., Manan Shah, Orsolya Lunacsek and Nicola A. Hanania. "Clinical
and Economic Burden of Patients Diagnosed with Copd with Comorbid
Cardiovascular Disease." Respiratory Medicine 105, no. 10 (2011): 1516-1522.

Divo, M., C. Cote, J. P. de Torres, C. Casanova, J. M. Marin, V. Pinto-Plata, J.
Zulueta, C. Cabrera, J. Zagaceta, G. Hunninghake, B. Celli and Bode
Collaborative Group. "Comorbidities and Risk of Mortality in Patients with

51

Chronic Obstructive Pulmonary Disease." American Journal of Respiratory
and Critical Care Medicine 186, no. 2 (2012): 155-61.

Drivenes, E., A. Ostrem and H. Melbye. "Predictors of Ics/Laba Prescribing in Copd
Patients: A Study from General Practice." BMC Family Practice 15, (2014):
42.

Falk, Jeremy A., Steven Kadiev, Gerard J. Criner, Steven M. Scharf, Omar A. Minai
and Philip Diaz. "Cardiac Disease in Chronic Obstructive Pulmonary Disease."
Proceedings of the American Thoracic Society 5, no. 4 (2008): 543-548.

Feary, J. R., L. C. Rodrigues, C. J. Smith, R. B. Hubbard and J. E. Gibson.
"Prevalence of Major Comorbidities in Subjects with Copd and Incidence of
Myocardial Infarction and Stroke: A Comprehensive Analysis Using Data
from Primary Care." Thorax 65, no. 11 (2010): 956-62.

Ferguson, G. T., C. Funck-Brentano, T. Fischer, P. Darken and C. Reisner.
"Cardiovascular Safety of Salmeterol in Copd." Chest 123, no. 6 (2003): 181724.

Ford, E. S., D. M. Mannino, A. G. Wheaton, L. Presley-Cantrell, Y. Liu, W. H. Giles
and J. B. Croft. "Trends in the Use, Sociodemographic Correlates, and
Undertreatment of Prescription Medications for Chronic Obstructive
Pulmonary Disease among Adults with Chronic Obstructive Pulmonary
Disease in the United States from 1999 to 2010." PloS One 9, no. 4 (2014):
e95305.

Ford, Earl S., Janet B. Croft, David M. Mannino, Anne G. Wheaton, Xingyou Zhang
and Wayne H. Giles. "Copd Surveillance—United States, 1999-2011." Chest
144, no. 1 (2013): 284-305.

Global Initiative for Chronic Obstructive Lung Disease (GOLD), "Global Strategy for
the Diagnosis, Management and Prevention of Copd" Available from:
http://www.goldcopd.org/ (accessed November 20 2014).
52

Groenwold, R. H., F. de Vries, A. de Boer, W. R. Pestman, F. H. Rutten, A. W. Hoes
and O. H. Klungel. "Balance Measures for Propensity Score Methods: A
Clinical Example on Beta-Agonist Use and the Risk of Myocardial Infarction."
Pharmacoepidemiology and Drug Safety 20, no. 11 (2011): 1130-7.

Güder, Gülmisal, Susanne Brenner, Stefan Störk, Arno Hoes and Frans H. Rutten.
"Chronic Obstructive Pulmonary Disease in Heart Failure: Accurate Diagnosis
and Treatment." European Journal of Heart Failure 16, no. 12 (2014): 12731282.

Hanania, Nicola A. and James F. Donohue. "Pharmacologic Interventions in Chronic
Obstructive Pulmonary Disease." Proceedings of the American Thoracic
Society 4, no. 7 (2007): 526-534.

Hawkins, Nathaniel M., Mark C. Petrie, Michael R. MacDonald, Pardeep S. Jhund,
Leonardo M. Fabbri, John Wikstrand and John J. V. McMurray. "Heart Failure
and Chronic Obstructive Pulmonary Disease: The Quandary of Beta-Blockers
and Beta-Agonists." Journal of the American College of Cardiology 57, no. 21
(2011): 2127-2138.

Lamprecht, B., M. A. McBurnie, W. M. Vollmer, G. Gudmundsson, T. Welte, E.
Nizankowska-Mogilnicka, M. Studnicka, E. Bateman, J. M. Anto, P. Burney,
D. M. Mannino, S. A. Buist and Bold Collaborative Research Group. "Copd in
Never Smokers: Results from the Population-Based Burden of Obstructive
Lung Disease Study." Chest 139, no. 4 (2011): 752-63.

Lopez, A. D., K. Shibuya, C. Rao, C. D. Mathers, A. L. Hansell, L. S. Held, V.
Schmid and S. Buist. "Chronic Obstructive Pulmonary Disease: Current
Burden and Future Projections." European Respiratory Journal 27, no. 2
(2006): 397-412.

Macie, Christine, Kate Wooldrage, Jure Manfreda and Nicholas Anthonisen.
"Cardiovascular Morbidity and the Use of Inhaled Bronchodilators."
53

International Journal of Chronic Obstructive Pulmonary Disease 3, no. 1
(2008): 163.

Mannino, David M, D Thorn, A Swensen and F Holguin. "Prevalence and Outcomes
of Diabetes, Hypertension and Cardiovascular Disease in Copd." European
Respiratory Journal 32, no. 4 (2008): 962-969.

National Center for Health Statistics, "National Ambulatory Medical Care Survey"
Available at http://www.cdc.gov/nchs/ahcd/ahcd_questionnaires.htm (accessed
February 12 2015).

Ng, T. P., M. Niti, W. C. Tan, Z. Cao, K. C. Ong and P. Eng. "Depressive Symptoms
and Chronic Obstructive Pulmonary Disease: Effect on Mortality, Hospital
Readmission, Symptom Burden, Functional Status, and Quality of Life."
Archives of Internal Medicine 167, no. 1 (2007): 60-7.

Noteboom, B., S. Jenkins, A. Maiorana, N. Cecins, C. Ng and K. Hill. "Comorbidities
and Medication Burden in Patients with Chronic Obstructive Pulmonary
Disease Attending Pulmonary Rehabilitation." Journal of Cardiopulmonary
Rehabilitation and Prevention 34, no. 1 (2014): 75-9.

Osthoff, M., C. Jenkins and J. Leuppi. "Chronic Obstructive Pulmonary Disease--a
Treatable Disease." Swiss Medical Weekly 143, (2013): w13777.

Pumar, M. I., C. R. Gray, J. R. Walsh, I. A. Yang, T. A. Rolls and D. L. Ward.
"Anxiety and Depression-Important Psychological Comorbidities of Copd."
Journal of Thoracic Disease 6, no. 11 (2014): 1615-1631.

Salpeter, S. R., T. M. Ormiston and E. E. Salpeter. "Cardiovascular Effects of BetaAgonists in Patients with Asthma and Copd: A Meta-Analysis." Chest 125, no.
6 (2004): 2309-21.

54

Salvi, S. S. and P. J. Barnes. "Chronic Obstructive Pulmonary Disease in NonSmokers." Lancet 374, no. 9691 (2009): 733-43.

Schnell, K., C. O. Weiss, T. Lee, J. A. Krishnan, B. Leff, J. L. Wolff and C. Boyd.
"The Prevalence of Clinically-Relevant Comorbid Conditions in Patients with
Physician-Diagnosed Copd: A Cross-Sectional Study Using Data from Nhanes
1999-2008." BMC Pulmonary Medicine 12, no. 26 (2012): 1471-2466.

Sin, D. D., N. R. Anthonisen, J. B. Soriano and A. G. Agusti. "Mortality in Copd: Role
of Comorbidities." European Respiratory Journal 28, no. 6 (2006): 1245-1257.

Singh, Sonal, Yoon K Loke, Paul Enright and Curt D Furberg. "Pro-Arrhythmic and
Pro-Ischaemic Effects of Inhaled Anticholinergic Medications." Thorax 68, no.
1 (2013): 114-116.

Smith, M. C. and J. P. Wrobel. "Epidemiology and Clinical Impact of Major
Comorbidities in Patients with Copd." International Journal of Chronic
Obstructive Pulmonary Disease 9, (2014): 871-88.

Souverein, P C, A Berard, T P Van Staa, C Cooper, A C G Egberts, H G M Leufkens
and B R Walker. "Use of Oral Glucocorticoids and Risk of Cardiovascular and
Cerebrovascular Disease in a Population Based Case–Control Study." Heart
90, no. 8 (2004): 859-865.

Suh, D. C., H. Lau, S. M. Pokras, I. S. Choi and E. Valiyeva. "Sex Differences in
Ambulatory Visits for Chronic Obstructive Pulmonary Disease, Based on the
National Ambulatory Medical Care Survey and the National Hospital
Ambulatory Medical Care Survey from 1995 to 2004." Respiratory Care 53,
no. 11 (2008): 1461-9.

Van Noord, J. A., P. J. Cornelissen, J. L. Aumann, J. Platz, A. Mueller and C. Fogarty.
"The Efficacy of Tiotropium Administered Via Respimat Soft Mist Inhaler or
Handihaler in Copd Patients." Respiratory Medicine 103, no. 1 (2009): 22-9.

55

Vanfleteren, Legw, M. A. Spruit, M. Groenen, S. Gaffron, V. P. M. van Empel, P. L.
B. Bruijnzeel, E. P. A. Rutten, J. O. t Roodt, E. F. M. Wouters and F. M. E.
Franssen. "Clusters of Comorbidities Based on Validated Objective
Measurements and Systemic Inflammation in Patients with Chronic
Obstructive Pulmonary Disease." American Journal of Respiratory and
Critical Care Medicine 187, no. 7 (2013): 728-735.

Verhamme, K. M., A. Afonso, S. Romio, B. C. Stricker, G. G. Brusselle and M. C.
Sturkenboom. "Use of Tiotropium Respimat Soft Mist Inhaler Versus
Handihaler and Mortality in Patients with Copd." European Respiratory
Journal 42, no. 3 (2013): 606-15.

Vos, Theo, Abraham D. Flaxman, Mohsen Naghavi, Rafael Lozano, Catherine
Michaud, Majid Ezzati. "Years Lived with Disability (Ylds) for 1160 Sequelae
of 289 Diseases and Injuries 1990–2010: A Systematic Analysis for the Global
Burden of Disease Study 2010." The Lancet 380, no. 9859 (2012): 2163-2196.

Wilchesky, Machelle, Pierre Ernst, James M. Brophy, Robert W. Platt and Samy
Suissa. "Bronchodilator Use and the Risk of Arrhythmia in Copd: Part 1:
Saskatchewan Cohort Study." Chest 142, no. 2 (2012): 298-304.

Wilchesky, Machelle, Pierre Ernst, James M. Brophy, Robert W. Platt and Samy
Suissa. "Bronchodilator Use and the Risk of Arrhythmia in Copd: Part 2:
Reassessment in the Larger Quebec Cohort." Chest 142, no. 2 (2012): 305-311.

World Health Organization, "Global Surveillance, Prevention and Control of Chronic
Respiratory Diseases: A Comprehensive Approach" Available from:
http://whqlibdoc.who.int/publications/2007/9789241563468_eng.pdf.
(accessed January 2 2015).

56

